Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Mammary Gland Biology and Neoplasia
Published in: Journal of Mammary Gland Biology and Neoplasia 1/2013

01-03-2013

Impaired Mitochondrial Metabolism and Mammary Carcinogenesis

Authors: Nagendra Yadava, Sallie S. Schneider, D. Joseph Jerry, Chul Kim

Published in: Journal of Mammary Gland Biology and Neoplasia | Issue 1/2013

Login to get access

Abstract

Mitochondrial oxidative metabolism plays a key role in meeting energetic demands of cells by oxidative phosphorylation (OxPhos). Here, we have briefly discussed (a) the dynamic relationship that exists among glycolysis, the tricarboxylic acid (TCA) cycle, and OxPhos; (b) the evidence of impaired OxPhos (i.e. mitochondrial dysfunction) in breast cancer; (c) the mechanisms by which mitochondrial dysfunction can predispose to cancer; and (d) the effects of host and environmental factors that can negatively affect mitochondrial function. We propose that impaired OxPhos could increase susceptibility to breast cancer via suppression of the p53 pathway, which plays a critical role in preventing tumorigenesis. OxPhos is sensitive to a large number of factors intrinsic to the host (e.g. inflammation) as well as environmental exposures (e.g. pesticides, herbicides and other compounds). Polymorphisms in over 143 genes can also influence the OxPhos system. Therefore, declining mitochondrial oxidative metabolism with age due to host and environmental exposures could be a common mechanism predisposing to cancer.
Literature
1.
Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27:441–64.PubMedCrossRef
2.
Lei J, Feng D, Zhang Y, Zhao FQ, Wu Z, San GA, et al. Nutritional and regulatory role of branched-chain amino acids in lactation. Front Biosci. 2012;17:2725–39.PubMedCrossRef
3.
Owen OE, Kalhan SC, Hanson RW. The key role of anaplerosis and cataplerosis for citric acid cycle function. J Biol Chem. 2002;277:30409–12.PubMedCrossRef
4.
5.
Ying W, Alano CC, Garnier P, Swanson RA. NAD + as a metabolic link between DNA damage and cell death. J Neurosci Res. 2005;79:216–23.PubMedCrossRef
6.
Bender K, Newsholme P, Brennan L, Maechler P. The importance of redox shuttles to pancreatic beta-cell energy metabolism and function. Biochem Soc Trans. 2006;34:811–4.PubMedCrossRef
7.
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.CrossRef
8.
Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, Parslow D, et al. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol. 2007;292:C125–36.PubMedCrossRef
9.
Nicholls DG, Ferguson SJ. Bioenergetics. 3rd ed. London: Academic; 2002.
10.
Watt IN, Montgomery MG, Runswick MJ, Leslie AG, Walker JE. Bioenergetic cost of making an adenosine triphosphate molecule in animal mitochondria. Proc Natl Acad Sci USA. 2010;107:16823–7.PubMedCrossRef
11.
Donnelly M, Scheffler IE. Energy metabolism in respiration-deficient and wild type Chinese hamster fibroblasts in culture. J Cell Physiol. 1976;89:39–51.PubMedCrossRef
12.
Li P, Knabe DA, Kim SW, Lynch CJ, Hutson SM, Wu G. Lactating porcine mammary tissue catabolizes branched-chain amino acids for glutamine and aspartate synthesis. J Nutr. 2009;139:1502–9.PubMedCrossRef
13.
Lei J, Feng D, Zhang Y, Dahanayaka S, Li X, Yao K, et al. Regulation of leucine catabolism by metabolic fuels in mammary epithelial cells. Amino Acids. 2012.
14.
Nicholls DG, Shepherd D, Garland PB. A continuous recording technique for the measurement of carbon dioxide, and its application to mitochondrial oxidation and decarboxylation reactions. Biochem J. 1967;103:677–91.PubMed
15.
Nicholls DG, Darley-Usmar VM, Wu M, Jensen PB, Rogers GW, Ferrick DA. Bioenergetic profile experiment using C2C12 myoblast cells. J Vis Exp. 2010.
16.
Ditta G, Soderberg K, Landy F, Scheffler IE. The selection of Chinese hamster cells deficient in oxidative energy metabolism. Somatic Cell Genet. 1976;2:331–44.PubMedCrossRef
17.
DeFrancesco L, Werntz D, Scheffler IE. Conditionally lethal mutations in chinese hamster cells. Characterization of a cell line with a possible defect in the Krebs cycle. J Cell Physiol. 1975;85:293–305.PubMedCrossRef
18.
DeFrancesco L, Scheffler IE, Bissell MJ. A respiration-deficient Chinese hamster cell line with a defect in NADH-coenzyme Q reductase. J Biol Chem. 1976;251:4588–95.PubMed
19.
Yadava N, Potluri P, Smith EN, Bisevac A, Scheffler IE. Species-specific and mutant MWFE proteins. Their effect on the assembly of a functional mammalian mitochondrial complex I. J Biol Chem. 2002;277:21221–30.PubMedCrossRef
20.
Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2012;481:380–4.
21.
Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2012;481:385–8.
22.
Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 2005;8:311–21.PubMedCrossRef
23.
Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, Mates JM, et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci USA. 2011;108:8674–9.PubMedCrossRef
24.
Fan TW, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M, et al. Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol Cancer. 2009;8:41.PubMedCrossRef
25.
Christian BE, Spremulli LL. Mechanism of protein biosynthesis in mammalian mitochondria. Biochim Biophys Acta. 2012;1819:1035–54.PubMedCrossRef
26.
Ghezzi D, Zeviani M. Assembly factors of human mitochondrial respiratory chain complexes: physiology and pathophysiology. Adv Exp Med Biol. 2012;748:65–106.PubMedCrossRef
27.
28.
Chen YC, Taylor EB, Dephoure N, Heo JM, Tonhato A, Papandreou I, et al. Identification of a protein mediating respiratory supercomplex stability. Cell Metab. 2012;15:348–60.PubMedCrossRef
29.
30.
Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11:325–37.PubMedCrossRef
31.
Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol. 2000;27:683–7.PubMedCrossRef
32.
Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005;11:2785–808.PubMedCrossRef
33.
Kostakoglu L, Goldsmith SJ. 18 F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med. 2003;44:224–39.PubMed
34.
Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18:3495–502.PubMed
35.
Xu HN, Tchou J, Chance B, Li LZ. Imaging the redox States of human breast cancer core biopsies. Adv Exp Med Biol. 2013;765:343–9.PubMedCrossRef
36.
Xu HN, Nioka S, Glickson JD, Chance B, Li LZ. Quantitative mitochondrial redox imaging of breast cancer metastatic potential. J Biomed Opt. 2010;15:036010.PubMedCrossRef
37.
Chandra D, Singh KK. Genetic insights into OXPHOS defect and its role in cancer. Biochim Biophys Acta. 2010;1807:620–5.PubMed
38.
Simonnet H, Demont J, Pfeiffer K, Guenaneche L, Bouvier R, Brandt U, et al. Mitochondrial complex I is deficient in renal oncocytomas. Carcinogenesis. 2003;24:1461–6.PubMedCrossRef
39.
bu-Amero KK, Alzahrani AS, Zou M, Shi Y. High frequency of somatic mitochondrial DNA mutations in human thyroid carcinomas and complex I respiratory defect in thyroid cancer cell lines. Oncogene. 2005;24:1455–60.CrossRef
40.
Dasgupta S, Soudry E, Mukhopadhyay N, Shao C, Yee J, Lam S, et al. Mitochondrial DNA mutations in respiratory complex-I in never-smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation. J Cell Physiol. 2011.
41.
Theodoratou E, Din FV, Farrington SM, Cetnarskyj R, Barnetson RA, Porteous ME, et al. Association between common mtDNA variants and all-cause or colorectal cancer mortality. Carcinogenesis. 2010;31:296–301.PubMedCrossRef
42.
Gasparre G, Hervouet E, de Laplanche E, Demont J, Pennisi LF, Colombel M, et al. Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Hum Mol Genet. 2008;17:986–95.PubMedCrossRef
43.
Mayr JA, Meierhofer D, Zimmermann F, Feichtinger R, Kogler C, Ratschek M, et al. Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. Clin Cancer Res. 2008;14:2270–5.PubMedCrossRef
44.
Canter JA, Kallianpur AR, Parl FF, Millikan RC. Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res. 2005;65:8028–33.PubMed
45.
Darvishi K, Sharma S, Bhat AK, Rai E, Bamezai RN. Mitochondrial DNA G10398A polymorphism imparts maternal Haplogroup N a risk for breast and esophageal cancer. Cancer Lett. 2007;249:249–55.PubMedCrossRef
46.
Plak K, Czarnecka AM, Krawczyk T, Golik P, Bartnik E. Breast cancer as a mitochondrial disorder (Review). Oncol Rep. 2009;21:845–51.PubMed
47.
Minocherhomji S, Tollefsbol TO, Singh KK. Mitochondrial regulation of epigenetics and its role in human diseases. Epigenetics. 2012;7:326–34.PubMedCrossRef
48.
Singh KK, Ayyasamy V, Owens KM, Koul MS, Vujcic M. Mutations in mitochondrial DNA polymerase-gamma promote breast tumorigenesis. J Hum Genet. 2009;54:516–24.PubMedCrossRef
49.
Baysal BE, Willett-Brozick JE, Lawrence EC, Drovdlic CM, Savul SA, McLeod DR, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet. 2002;39:178–83.PubMedCrossRef
50.
Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287:848–51.PubMedCrossRef
51.
Bardella C, Pollard PJ, Tomlinson I. SDH mutations in cancer. Biochim Biophys Acta. 2011;1807:1432–43.PubMedCrossRef
52.
Kunst HP, Rutten MH, de Monnink JP, Hoefsloot LH, Timmers HJ, Marres HA, et al. SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. Clin Cancer Res. 2011;17:247–54.PubMedCrossRef
53.
Bayley JP, Kunst HP, Cascon A, Sampietro ML, Gaal J, Korpershoek E, et al. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol. 2010;11:366–72.PubMedCrossRef
54.
Ni Y, He X, Chen J, Moline J, Mester J, Orloff MS, et al. Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. Hum Mol Genet. 2012;21:300–10.PubMedCrossRef
55.
Zimmermann FA, Mayr JA, Neureiter D, Feichtinger R, Alinger B, Jones ND, et al. Lack of complex I is associated with oncocytic thyroid tumours. Br J Cancer. 2009;100:1434–7.PubMedCrossRef
56.
Imanishi H, Hattori K, Wada R, Ishikawa K, Fukuda S, Takenaga K, et al. Mitochondrial DNA mutations regulate metastasis of human breast cancer cells. PLoS One. 2011;6:e23401.PubMedCrossRef
57.
Kulawiec M, Owens KM. Singh KK: mtDNA G10398A variant in African-American women with breast cancer provides resistance to apoptosis and promotes metastasis in mice. J Hum Genet. 2009;54:647–54.PubMedCrossRef
58.
Owens KM, Kulawiec M, Desouki MM, Vanniarajan A, Singh KK. Impaired OXPHOS complex III in breast cancer. PLoS One. 2011;6:e23846.PubMedCrossRef
59.
Putignani L, Raffa S, Pescosolido R, Aimati L, Signore F, Torrisi MR, et al. Alteration of expression levels of the oxidative phosphorylation system (OXPHOS) in breast cancer cell mitochondria. Breast Cancer Res Treat. 2008;110:439–52.PubMedCrossRef
60.
Suhane S, Berel D, Ramanujan VK. Biomarker signatures of mitochondrial NDUFS3 in invasive breast carcinoma. Biochem Biophys Res Commun. 2011;412:590–5.PubMedCrossRef
61.
McKenzie M, Ryan MT. Assembly factors of human mitochondrial complex I and their defects in disease. IUBMB Life. 2010;62:497–502.PubMedCrossRef
62.
Isidoro A, Casado E, Redondo A, Acebo P, Espinosa E, Alonso AM, et al. Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis. 2005;26:2095–104.PubMedCrossRef
63.
Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamaria G, Kim H, et al. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res. 2002;62:6674–81.PubMed
64.
Sanchez-Cenizo L, Formentini L, Aldea M, Ortega AD, Garcia-Huerta P, Sanchez-Arago M, et al. The up-regulation of the ATPase Inhibitory Factor 1 (IF1) of the mitochondrial H + -ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype. J Biol Chem. 2010.
65.
Ayyasamy V, Owens KM, Desouki MM, Liang P, Bakin A, Thangaraj K, et al. Cellular model of Warburg effect identifies tumor promoting function of UCP2 in breast cancer and its suppression by genipin. PLoS One. 2011;6:e24792.PubMedCrossRef
66.
Sotgia F, Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, Birbe RC, Witkiewicz AK, et al. Mitochondrial metabolism in cancer metastasis: visualizing tumor cell mitochondria and the “reverse Warburg effect“in positive lymph node tissue. Cell Cycle. 2012;11:1445–54.PubMedCrossRef
67.
Salem AF, Whitaker-Menezes D, Lin Z, Tanowitz HB, Al-Zoubi MS, Howell A, et al. Two-compartment tumor metabolism: autophagy in the tumor microenvironment and oxidative mitochondrial metabolism (OXPHOS) in cancer cells. Cell Cycle. 2012;11:2545–56.PubMedCrossRef
68.
Balliet RM, Capparelli C, Guido C, Pestell TG, Martinez-Outschoorn UE, Lin Z, et al. Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth: understanding the aging and cancer connection. Cell Cycle. 2011;10:4065–73.PubMedCrossRef
69.
70.
71.
Perkins ND. The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer. 2012;12:121–32.PubMed
72.
Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci USA. 2005;102:719–24.PubMedCrossRef
73.
Kulawiec M, Safina A, Desouki MM, Still I, Matsui S, Bakin A, et al. Tumorigenic transformation of human breast epithelial cells induced by mitochondrial DNA depletion. Cancer Biol Ther. 2008;7:1732–43.PubMedCrossRef
74.
Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA. 2008;105:18782–7.PubMedCrossRef
75.
Lum JJ, Bui T, Gruber M, Gordan JD, DeBerardinis RJ, Covello KL, et al. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev. 2007;21:1037–49.PubMedCrossRef
76.
Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, et al. p53 regulates mitochondrial respiration. Science. 2006;312:1650–3.PubMedCrossRef
77.
Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126:107–20.PubMedCrossRef
78.
Yang D, Wang MT, Tang Y, Chen Y, Jiang H, Jones TT, et al. Impairment of mitochondrial respiration in mouse fibroblasts by oncogenic H-RAS(Q61L). Cancer Biol Ther. 2010;9.
79.
DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11–20.PubMedCrossRef
80.
Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 2010;330:1340–4.PubMedCrossRef
81.
Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012;21:297–308.PubMedCrossRef
82.
Shen L, Wei J, Chen T, He J, Qu J, He X, et al. Evaluating mitochondrial DNA in patients with breast cancer and benign breast disease. J Cancer Res Clin Oncol. 2011;137:669–75.PubMedCrossRef
83.
Chen PL, Chen CF, Chen Y, Guo XE, Huang CK, Shew JY, et al. Mitochondrial genome instability resulting from SUV3 haploinsufficiency leads to tumorigenesis and shortened lifespan. Oncogene. 2012.
84.
Hashizume O, Shimizu A, Yokota M, Sugiyama A, Nakada K, Miyoshi H, et al. Specific mitochondrial DNA mutation in mice regulates diabetes and lymphoma development. Proc Natl Acad Sci USA. 2012;109:10528–33.PubMedCrossRef
85.
Lahiry L, Saha B, Chakraborty J, Adhikary A, Mohanty S, Hossain DM, et al. Theaflavins target Fas/caspase-8 and Akt/pBad pathways to induce apoptosis in p53-mutated human breast cancer cells. Carcinogenesis. 2009.
86.
Gochhait S, Bhatt A, Sharma S, Singh YP, Gupta P, Bamezai RN. Concomitant presence of mutations in mitochondrial genome and p53 in cancer development - a study in north Indian sporadic breast and esophageal cancer patients. Int J Cancer. 2008;123:2580–6.PubMedCrossRef
87.
Pelicano H, Xu RH, Du M, Feng L, Sasaki R, Carew JS, et al. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol. 2006;175:913–23.PubMedCrossRef
88.
Compton S, Kim C, Griner NB, Potluri P, Scheffler IE, Sen S, et al. Mitochondrial dysfunction impairs tumor suppressor p53 expression/function. J Biol Chem. 2011;286:20297–312.PubMedCrossRef
89.
Porcelli AM, Ghelli A, Ceccarelli C, Lang M, Cenacchi G, Capristo M, et al. The genetic and metabolic signature of oncocytic transformation implicates HIF1{alpha} destabilization. Hum Mol Genet. 2009;19:1019–32.PubMedCrossRef
90.
Sun W, Zhou S, Chang SS, McFate T, Verma A, Califano JA. Mitochondrial mutations contribute to HIF1alpha accumulation via increased reactive oxygen species and up-regulated pyruvate dehydrogenease kinase 2 in head and neck squamous cell carcinoma. Clin Cancer Res. 2009;15:476–84.PubMedCrossRef
91.
Briere JJ, Favier J, Benit P, El Ghouzzi V, Lorenzato A, Rabier D, et al. Mitochondrial succinate is instrumental for HIF1alpha nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Hum Mol Genet. 2005;14:3263–9.PubMedCrossRef
92.
van Waveren C, Sun Y, Cheung HS, Moraes CT. Oxidative phosphorylation dysfunction modulates expression of extracellular matrix—remodeling genes and invasion. Carcinogenesis. 2006;27:409–18.PubMedCrossRef
93.
Dey R, Moraes CT. Lack of oxidative phosphorylation and low mitochondrial membrane potential decrease susceptibility to apoptosis and do not modulate the protective effect of Bcl-x(L) in osteosarcoma cells. J Biol Chem. 2000;275:7087–94.PubMedCrossRef
94.
Acebo P, Giner D, Calvo P, Blanco-Rivero A, Ortega AD, Fernandez PL, et al. Cancer abolishes the tissue type-specific differences in the phenotype of energetic metabolism. Transl Oncol. 2009;2:138–45.PubMed
95.
Kamp DW, Shacter E, Weitzman SA. Chronic inflammation and cancer: the role of the mitochondria. Oncology (Williston Park). 2011;25:400–10. 413.
96.
Yang J, Staples O, Thomas LW, Briston T, Robson M, Poon E, et al. Human CHCHD4 mitochondrial proteins regulate cellular oxygen consumption rate and metabolism and provide a critical role in hypoxia signaling and tumor progression. J Clin Invest. 2012;122:600–11.PubMedCrossRef
97.
Haigis MC, Deng CX, Finley LW, Kim HS, Gius D. SIRT3 is a mitochondrial tumor suppressor: a scientific tale that connects aberrant cellular ROS, the Warburg effect, and carcinogenesis. Cancer Res. 2012;72:2468–72.PubMedCrossRef
98.
Tello D, Balsa E, Acosta-Iborra B, Fuertes-Yebra E, Elorza A, Ordonez A, et al. Induction of the mitochondrial NDUFA4L2 protein by HIF-1alpha decreases oxygen consumption by inhibiting Complex I activity. Cell Metab. 2011;14:768–79.PubMedCrossRef
99.
Asher G, Lotem J, Kama R, Sachs L, Shaul Y. NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci USA. 2002;99:3099–104.PubMedCrossRef
100.
Dimri G, Band H, Band V. Mammary epithelial cell transformation: insights from cell culture and mouse models. Breast Cancer Res. 2005;7:171–9.PubMedCrossRef
101.
Zhao JJ, Gjoerup OV, Subramanian RR, Cheng Y, Chen W, Roberts TM, et al. Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell. 2003;3:483–95.PubMedCrossRef
102.
Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE, et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature. 2004;429:417–23.PubMedCrossRef
103.
Feng Z, Hu W, Teresky AK, Hernando E, Cordon-Cardo C, Levine AJ. Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci USA. 2007;104:16633–8.PubMedCrossRef
104.
Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet. 2005;39:359–407.PubMedCrossRef
105.
Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009;27:1250–6.PubMedCrossRef
106.
Hinkal G, Parikh N, Donehower LA. Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression. PLoS One. 2009;4:e6654.PubMedCrossRef
107.
Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature. 2006;443:214–7.PubMedCrossRef
108.
Kemp CJ, Wheldon T, Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet. 1994;8:66–9.PubMedCrossRef
109.
Sahin E, Colla S, Liesa M, Moslehi J, Muller FL, Guo M, et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature. 2011;470:359–65.PubMedCrossRef
110.
111.
Kulawiec M, Ayyasamy V, Singh KK. p53 regulates mtDNA copy number and mitocheckpoint pathway. J Carcinog. 2009;8:8.PubMedCrossRef
112.
Achanta G, Sasaki R, Feng L, Carew JS, Lu W, Pelicano H, et al. Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. EMBO J. 2005;24:3482–92.PubMedCrossRef
113.
Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009;139:693–706.PubMedCrossRef
114.
Shamanin VA, Androphy EJ. Immortalization of human mammary epithelial cells is associated with inactivation of the p14ARF-p53 pathway. Mol Cell Biol. 2004;24:2144–52.PubMedCrossRef
115.
Coloff JL, Macintyre AN, Nichols AG, Liu T, Gallo CA, Plas DR, et al. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res. 2011;71:5204–13.PubMedCrossRef
116.
Plas DR, Thompson CB. Akt-dependent transformation: there is more to growth than just surviving. Oncogene. 2005;24:7435–42.PubMedCrossRef
117.
Mauro C, Leow SC, Anso E, Rocha S, Thotakura AK, Tornatore L, et al. NF-kappaB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nat Cell Biol. 2011;13:1272–9.PubMedCrossRef
118.
119.
Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137:413–31.PubMedCrossRef
120.
Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 2003;11:577–90.PubMedCrossRef
121.
Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science. 2005;309:1732–5.PubMedCrossRef
122.
Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303:1010–4.PubMedCrossRef
123.
Jackson JG, Post SM, Lozano G. Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. J Pathol. 2011;223:127–36.PubMedCrossRef
124.
Miwa S, Brand MD. The topology of superoxide production by complex III and glycerol 3-phosphate dehydrogenase in Drosophila mitochondria. Biochim Biophys Acta. 2005;1709:214–9.PubMedCrossRef
125.
Lambert AJ, Brand MD. Superoxide production by NADH:ubiquinone oxidoreductase (complex I) depends on the pH gradient across the mitochondrial inner membrane. Biochem J. 2004;382:511–7.PubMedCrossRef
126.
Quinlan CL, Orr AL, Perevoshchikova IV, Treberg JR, Ackrell BA, Brand MD. Mitochondrial complex II can generate reactive oxygen species at high rates in both the forward and reverse reactions. J Biol Chem. 2012;287:27255–64.PubMedCrossRef
127.
128.
Sung HJ, Ma W, Wang PY, Hynes J, O'Riordan TC, Combs CA, et al. Mitochondrial respiration protects against oxygen-associated DNA damage. Nat Commun. 2010;1:5.PubMedCrossRef
129.
Desler C, Munch-Petersen B, Stevnsner T, Matsui S, Kulawiec M, Singh KK, et al. Mitochondria as determinant of nucleotide pools and chromosomal stability. Mutat Res. 2007;625:112–24.PubMedCrossRef
130.
Finley LW, Carracedo A, Lee J, Souza A, Egia A, Zhang J, et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell. 2011;19:416–28.PubMedCrossRef
131.
Goh J, Enns L, Fatemie S, Hopkins H, Morton J, Pettan-Brewer C, et al. Mitochondrial targeted catalase suppresses invasive breast cancer in mice. BMC Cancer. 2011;11:191.PubMedCrossRef
132.
Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle. 2010;9:3256–76.PubMedCrossRef
133.
Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol. 2012;7:423–67.PubMedCrossRef
134.
Sotgia F, Martinez-Outschoorn UE, Pavlides S, Howell A, Pestell RG, Lisanti MP. Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Res. 2011;13:213.PubMedCrossRef
135.
Bosch M, Mari M, Herms A, Fernandez A, Fajardo A, Kassan A, et al. Caveolin-1 deficiency causes cholesterol-dependent mitochondrial dysfunction and apoptotic susceptibility. Curr Biol. 2011;21:681–6.PubMedCrossRef
136.
Bosch M, Mari M, Gross SP, Fernandez-Checa JC, Pol A. Mitochondrial cholesterol: a connection between caveolin, metabolism, and disease. Traffic. 2011;12:1483–9.PubMedCrossRef
137.
Garcia-Ruiz C, Mari M, Colell A, Morales A, Caballero F, Montero J, et al. Mitochondrial cholesterol in health and disease. Histol Histopathol. 2009;24:117–32.PubMed
138.
Wallace DC. The epigenome and the mitochondrion: bioenergetics and the environment. Genes Dev. 2010;24:1571–3.PubMedCrossRef
139.
Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science. 2009;324:1076–80.PubMedCrossRef
140.
Smiraglia DJ, Kulawiec M, Bistulfi GL, Gupta SG, Singh KK. A novel role for mitochondria in regulating epigenetic modification in the nucleus. Cancer Biol Ther. 2008;7:1182–90.PubMedCrossRef
141.
Bahar R, Hartmann CH, Rodriguez KA, Denny AD, Busuttil RA, Dolle ME, et al. Increased cell-to-cell variation in gene expression in ageing mouse heart. Nature. 2006;441:1011–4.PubMedCrossRef
142.
Bai RK, Leal SM, Covarrubias D, Liu A, Wong LJ. Mitochondrial genetic background modifies breast cancer risk. Cancer Res. 2007;67:4687–94.PubMedCrossRef
143.
Potluri P, Davila A, Ruiz-Pesini E, Mishmar D, O'Hearn S, Hancock S, et al. A novel NDUFA1 mutation leads to a progressive mitochondrial complex I-specific neurodegenerative disease. Mol Genet Metab. 2009;96:189–95.PubMedCrossRef
144.
Sampey BP, Freemerman AJ, Zhang J, Kuan PF, Galanko JA, O'Connell TM, et al. Metabolomic profiling reveals mitochondrial-derived lipid biomarkers that drive obesity-associated inflammation. PLoS One. 2012;7:e38812.PubMedCrossRef
145.
Perfield JW, Lee Y, Shulman GI, Samuel VT, Jurczak MJ, Chang E, et al. Tumor progression locus 2 (TPL2) regulates obesity-associated inflammation and insulin resistance. Diabetes. 2011;60:1168–76.PubMedCrossRef
146.
Park J, Kusminski CM, Chua SC, Scherer PE. Leptin receptor signaling supports cancer cell metabolism through suppression of mitochondrial respiration in vivo. Am J Pathol. 2010;177:3133–44.PubMedCrossRef
147.
Remels AH, Gosker HR, Schrauwen P, Hommelberg PP, Sliwinski P, Polkey M, et al. TNF-alpha impairs regulation of muscle oxidative phenotype: implications for cachexia? FASEB J. 2010;24:5052–62.PubMedCrossRef
148.
Samavati L, Lee I, Mathes I, Lottspeich F, Huttemann M. Tumor necrosis factor alpha inhibits oxidative phosphorylation through tyrosine phosphorylation at subunit I of cytochrome c oxidase. J Biol Chem. 2008;283:21134–44.PubMedCrossRef
149.
Suematsu N, Tsutsui H, Wen J, Kang D, Ikeuchi M, Ide T, et al. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation. 2003;107:1418–23.PubMedCrossRef
150.
Lee SY, Jeon HM, Ju MK, Kim CH, Yoon G, Han SI, et al. Wnt/Snail signaling regulates cytochrome C oxidase and glucose metabolism. Cancer Res. 2012;72:3607–17.PubMedCrossRef
151.
Garcia-Ruiz I, Rodriguez-Juan C, az-Sanjuan T, del Hoyo P, Colina F, Munoz-Yague T, et al. Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. Hepatology. 2006;44:581–91.PubMedCrossRef
152.
Ojalvo LS, Whittaker CA, Condeelis JS, Pollard JW. Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J Immunol. 2010;184:702–12.PubMedCrossRef
153.
Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell. 2011;145:926–40.PubMedCrossRef
154.
Maciver NJ, Jacobs SR, Wieman HL, Wofford JA, Coloff JL, Rathmell JC. Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J Leukoc Biol. 2008;84:949–57.PubMedCrossRef
155.
Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature. 2009;460:103–7.PubMedCrossRef
156.
Krawczyk CM, Holowka T, Sun J, Blagih J, Amiel E, DeBerardinis RJ, et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood. 2010;115:4742–9.PubMedCrossRef
157.
Kasahara E, Sekiyama A, Hori M, Hara K, Takahashi N, Konishi M, et al. Mitochondrial density contributes to the immune response of macrophages to lipopolysaccharide via the MAPK pathway. FEBS Lett. 2011;585:2263–8.PubMedCrossRef
158.
Charni S, de Bettignies G, Rathore MG, Aguilo JI, van den Elsen PJ, Haouzi D, et al. Oxidative phosphorylation induces de novo expression of the MHC class I in tumor cells through the ERK5 pathway. J Immunol. 2010;185:3498–503.PubMedCrossRef
159.
Hanekamp JS, Okumi M, Tena A, Arn S, Yamada K, Sachs DH. Cytoplasmic inheritance of transplantation antigens in animals produced by nuclear transfer. Transplantation. 2009;88:30–7.PubMedCrossRef
160.
Ishikawa K, Toyama-Sorimachi N, Nakada K, Morimoto M, Imanishi H, Yoshizaki M, et al. The innate immune system in host mice targets cells with allogenic mitochondrial DNA. J Exp Med. 2010;207:2297–305.PubMedCrossRef
161.
Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464:104–7.PubMedCrossRef
162.
Raoof M, Zhang Q, Itagaki K, Hauser CJ. Mitochondrial peptides are potent immune activators that activate human neutrophils via FPR-1. J Trauma. 2010;68:1328–32.PubMedCrossRef
163.
Johnson RF, Witzel II, Perkins ND. p53-dependent regulation of mitochondrial energy production by the RelA subunit of NF-kappaB. Cancer Res. 2011;71:5588–97.PubMedCrossRef
164.
St-Hilaire S, Mandal R, Commendador A, Mannel S, Derryberry D. Estrogen receptor positive breast cancers and their association with environmental factors. Int J Health Geogr. 2011;10:32.PubMedCrossRef
165.
Chen JQ, Brown TR, Russo J. Regulation of energy metabolism pathways by estrogens and estrogenic chemicals and potential implications in obesity associated with increased exposure to endocrine disruptors. Biochim Biophys Acta. 2009;1793:1128–43.PubMedCrossRef
166.
Rosca MG, Vazquez EJ, Chen Q, Kerner J, Kern TS, Hoppel CL. Oxidation of Fatty acids is the source of increased mitochondrial reactive oxygen species production in kidney cortical tubules in early diabetes. Diabetes. 2012;61:2074–83.PubMedCrossRef
167.
Chang EC, Charn TH, Park SH, Helferich WG, Komm B, Katzenellenbogen JA, et al. Estrogen Receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding. Mol Endocrinol. 2008;22:1032–43.PubMedCrossRef
168.
Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen receptor beta: an overview and update. Nucl Recept Signal. 2008;6:e003.PubMed
169.
Hodges-Gallagher L, Valentine CD, El BS, Kushner PJ. Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res Treat. 2008;109:241–50.PubMedCrossRef
170.
Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology. 1998;139:4252–63.PubMedCrossRef
171.
Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997;138:863–70.PubMedCrossRef
172.
Gavrilova-Jordan LP, Price TM. Actions of steroids in mitochondria. Semin Reprod Med. 2007;25:154–64.PubMedCrossRef
173.
Pedram A, Razandi M, Wallace DC, Levin ER. Functional estrogen receptors in the mitochondria of breast cancer cells. Mol Biol Cell. 2006;17:2125–37.PubMedCrossRef
174.
Hollerhage M, Matusch A, Champy P, Lombes A, Ruberg M, Oertel WH, et al. Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies. Exp Neurol. 2009;220:133–42.PubMedCrossRef
175.
Sherer TB, Richardson JR, Testa CM, Seo BB, Panov AV, Yagi T, et al. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J Neurochem. 2007;100:1469–79.PubMed
176.
Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci. 2000;3:1301–6.PubMedCrossRef
177.
Sereda B, Bouwman H, Kylin H. Comparing water, bovine milk, and indoor residual spraying as possible sources of DDT and pyrethroid residues in breast milk. J Toxicol Environ Health A. 2009;72:842–51.PubMedCrossRef
178.
Gassner B, Wuthrich A, Scholtysik G, Solioz M. The pyrethroids permethrin and cyhalothrin are potent inhibitors of the mitochondrial complex I. J Pharmacol Exp Ther. 1997;281:855–60.PubMed
179.
Hovey RC, Coder PS, Wolf JC, Sielken Jr RL, Tisdel MO, Breckenridge CB. Quantitative assessment of mammary gland development in female Long Evans rats following in utero exposure to atrazine. Toxicol Sci. 2011;119:380–90.PubMedCrossRef
180.
Simpkins JW, Swenberg JA, Weiss N, Brusick D, Eldridge JC, Stevens JT, et al. Atrazine and breast cancer: a framework assessment of the toxicological and epidemiological evidence. Toxicol Sci. 2011;123:441–59.PubMedCrossRef
181.
Lasserre JP, Fack F, Revets D, Planchon S, Renaut J, Hoffmann L, et al. Effects of the endocrine disruptors atrazine and PCB 153 on the protein expression of MCF-7 human cells. J Proteome Res. 2009;8:5485–96.PubMedCrossRef
182.
Lim S, Ahn SY, Song IC, Chung MH, Jang HC, Park KS, et al. Chronic exposure to the herbicide, atrazine, causes mitochondrial dysfunction and insulin resistance. PLoS One. 2009;4:e5186.PubMedCrossRef
183.
Yadava N, Nicholls DG. Spare respiratory capacity rather than oxidative stress regulates glutamate excitotoxicity after partial respiratory inhibition of mitochondrial complex I with rotenone. J Neurosci. 2007;27:7310–7.PubMedCrossRef
Metadata
Title
Impaired Mitochondrial Metabolism and Mammary Carcinogenesis
Authors
Nagendra Yadava
Sallie S. Schneider
D. Joseph Jerry
Chul Kim
Publication date
01-03-2013
Publisher
Springer US
Published in
Journal of Mammary Gland Biology and Neoplasia / Issue 1/2013
Print ISSN: 1083-3021
Electronic ISSN: 1573-7039
DOI
https://doi.org/10.1007/s10911-012-9271-3

Other articles of this Issue 1/2013

Journal of Mammary Gland Biology and Neoplasia 1/2013 Go to the issue

ReviewPaper

Smoking and Breast Cancer

ReviewPaper

Exposures to Synthetic Estrogens at Different Times During the Life, and Their Effect on Breast Cancer Risk

Preface

Preface

ReviewPaper

Endocrine Disruptors and the Breast: Early Life Effects and Later Life Disease

ReviewPaper

Metals and Breast Cancer

ReviewPaper

New Biological Insights on the Link Between Radiation Exposure and Breast Cancer Risk
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits